Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against certain of its officers and directors who may have breached the fiduciary duties they owed to the Company. A recently filed federal securities fraud class action complaint alleges that Alto Neuroscience, Inc., through certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #FastTrack--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophr ...

Group 1 - A class action has been filed on behalf of investors who purchased or acquired Alto Neuroscience, Inc. common stock related to its initial public offering (IPO) [1] - The IPO was conducted on or about February 2, 2024, and the class action covers securities acquired between February 2, 2024, and October 22, 2024 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the lead plaintiff deadline for a class action lawsuit related to the company's initial public offering and subsequent securities purchases [1]. Group 1: Class Action Details - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [7]. Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [7]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than the company had indicated, leading to overstated clinical, regulatory, and commercial prospects [7]. Stock Performance Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [7]. Next Steps for Investors - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 19, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and specializes in commercial and securities litigation [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against Alto Neuroscience - The complaint alleges that the company's product ALTO-100 was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical, regulatory, and commercial prospects [4]. - As a result of these misleading statements, Alto's business and financial prospects were also overstated, impacting the accuracy of the company's public statements [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [6].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder [2]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiff [3]. Group 2: Allegations Against the Company - The complaint alleges that the company misrepresented the effectiveness of ALTO-100, overstating its clinical, regulatory, and commercial prospects [2]. - As a result of these misrepresentations, the company's business and financial prospects were also overstated, leading to materially false and misleading public statements [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [8]. Group 1: Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [8]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than previously communicated, leading to overstated clinical, regulatory, and commercial prospects [8]. Group 2: Stock Price Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [8]. Group 3: Legal Process - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, have until September 19, 2025, to apply to be appointed as lead plaintiff in the lawsuit [8].

Summary of Alto Neuroscience FY Conference Call Company Overview - **Company**: Alto Neuroscience (NYSE: ANRO) - **Focus**: Precision psychiatry and biomarkers in neuropsychiatry, particularly in cognitive impairment and treatment-resistant depression [1][2] Key Points and Arguments Biomarker Selection and Research Approach - Alto emphasizes a dual approach to biomarker selection: understanding the biology of disorders and utilizing machine learning for predictive analysis [2][3] - The company prioritizes prospective replication of findings to ensure confidence in advancing drug development [3] FDA Guidelines and Regulatory Framework - Alto follows FDA's 2019 enrichment guidelines, which allow for the inclusion of biomarkers in clinical trials to enhance predictive value and reliability [6][7] - The Chief Medical Officer's experience with the FDA supports Alto's strategic alignment with regulatory expectations [7] Pipeline Overview - **ALTO-101**: A PDE4 inhibitor targeting cognitive impairment associated with schizophrenia (CIAS). Expected to read out results in the coming months [9][42] - **ALTO-207**: A combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The mechanism targets dopamine receptors, particularly the D3 subtype, to enhance efficacy while mitigating side effects [10][13][15] - **ALTO-300**: An adjunctive treatment for major depressive disorder (MDD) using agomelatine, with a focus on improving tolerability and efficacy [11][49] Clinical Efficacy and Data Insights - ALTO-207 has shown promising effect sizes in previous studies, with a Cohen's D of 0.9 indicating significant efficacy in TRD populations [14][24] - The EEG biomarker linked to ALTO-207 correlates with motivational deficits and anhedonia, providing insights into treatment response [19][20] Safety and Tolerability - The combination therapy of pramipexole and ondansetron aims to reduce nausea and vomiting, common side effects of pramipexole alone [15][29] - Monitoring for impulse control disorders is crucial, especially given pramipexole's history in Parkinson's patients [30][31] Study Design and Future Plans - Phase IIB trials for ALTO-207 are set to begin in the first half of the next year, with a robust design aimed at regulatory submission [35][36] - The ALTO-300 study is being upsized based on interim analysis findings, with a focus on rigorous patient screening and data integrity [49][50] Additional Important Insights - The need for effective treatments in neuropsychiatry is emphasized, particularly for populations with limited options [47] - Alto's commitment to high standards in clinical trial execution reflects a broader trend in the industry towards increased rigor and reliability [50] This summary encapsulates the critical aspects of Alto Neuroscience's conference call, highlighting the company's strategic focus, pipeline developments, and commitment to advancing neuropsychiatric treatments through innovative biomarker-driven approaches.